Biophytis Announces An Exclusive License Agreement With Blanver For BIO101 (20-hydroxyecdysone) In Latin American, Biophytis Will Be Able To Receive Up To €108M Including An Upfront Payment And Further Additional Milestone Payments
Portfolio Pulse from Benzinga Newsdesk
Biophytis has entered into an exclusive license agreement with Blanver for the commercialization of BIO101 in Latin America. Biophytis could receive up to €108M, including upfront and milestone payments. Blanver will handle registration, marketing, and commercialization of BIO101 for various indications once clinical development is completed.
June 20, 2024 | 8:59 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Biophytis has signed an exclusive license agreement with Blanver for the commercialization of BIO101 in Latin America, potentially earning up to €108M. Blanver will manage the registration, marketing, and commercialization of BIO101 for various indications.
The agreement with Blanver provides Biophytis with a significant revenue opportunity and a strong partner for the commercialization of BIO101 in Latin America. This partnership could positively impact Biophytis' stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100